Excellent treatment outcomes in children younger than 18 months with stage 4 MYCN nonamplified neuroblastomaopen access
- Authors
- Kim, C.[Kim, C.]; Choi, Y.B.[Choi, Y.B.]; Lee, J.W.[Lee, J.W.]; Yoo, K.H.[Yoo, K.H.]; Sung, K.W.[Sung, K.W.]; Koo, H.H.[Koo, H.H.]
- Issue Date
- 2018
- Publisher
- Korean Pediatric Society
- Keywords
- Infant; N-myc proto-oncogene protein; Neoplasm metastasis; Neuroblastoma
- Citation
- Korean Journal of Pediatrics, v.61, no.2, pp.53 - 58
- Indexed
- SCOPUS
KCI
- Journal Title
- Korean Journal of Pediatrics
- Volume
- 61
- Number
- 2
- Start Page
- 53
- End Page
- 58
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/24823
- DOI
- 10.3345/kjp.2018.61.2.53
- ISSN
- 1738-1061
- Abstract
- Purpose: Although the prognosis is generally good in patients with intermediate-risk neuroblastoma, no consensus has been reached on the ideal treatment regimen. This study analyzed treatment outcomes and toxicities in patients younger than 18 months with stage 4 MYCN nonamplified neuroblastoma. Methods: We retrospectively analyzed 20 patients younger than 18 months newly diagnosed with stage 4 MYCN nonamplified neuroblastoma between January 2009 and December 2015. Patients received 9 cycles of chemotherapy and surgery, with or without local radiotherapy, followed by 12 cycles of differentiation therapy with 13-cis-retinoic acid. Chemotherapy consisted of alternating cycles of cisplatin, etoposide, doxorubicin, and cyclophosphamide (CEDC) and ifosfamide, carboplatin, and etoposide (ICE) regimens. Results: The most common primary tumor site was the abdomen (85%), and the most common metastatic sites were the lymph nodes (65%), followed by the bones (60%), liver (55%), skin (45%), and bone marrow (25%). At the end of induction therapy, 14 patients (70%) achieved complete response, with 1 achieving very good partial response, 4 achieving partial response, and 1 showing mixed response. Nine patients (45%) received local radiotherapy. At a median follow-up of 47 months (range, 17–91 months), none of these patients experienced relapse, progression, or secondary malignancy, or died. Three years after chemotherapy completion, none of the patients had experienced grade ≥3 late adverse effects. Conclusion: Patients younger than 18 months with stage 4 MYCN nonamplified neuroblastoma showed excellent outcomes, without significant late adverse effects, when treated with alternating cycles of CEDC and ICE, followed by surgery and differentiation therapy. © 2018 by The Korean Pediatric Society.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/24823)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.